Regulatory Roundup: FDA Issues Warning Letter To Pfizer; And More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Issues Warning Letter To Pfizer; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Earlier this month, the US Food and Drug Administration issued a Warning Letter to the Global Research and Development division of Pfizer (New York) in London, Connecticut. The letter concerns an investigation that took place in spring 2009 which found that the manufacturer “did not adhere to the applicable statutory requirements and FDA regulations governing the conduct of clinical investigations.” Specifically, FDA pointed out the company’s failure to ensure proper monitoring of the investigation, including compliance with 21 CFR 312.50, and failure to keep investigators informed of new observations reported to the sponsor of the drug regarding adverse effects and safe use. Other recent Warning Letters can be found on the FDA CDER website.

FDA issued a consent decree last week to halt the marketing of an unapproved sterilization system manufactured by Steris (Mentor, OH). The company has been selling tabletop systems for endoscopes and other devices used to sterilize heat-sensitive instruments and medical devices. “When device manufacturers fail to comply with FDA’s regulations, they put patients at increased risk. As this consent decree shows, we will take whatever steps are necessary to make sure that all manufacturers are complying with FDA’s regulations,” said the FDA press release on the consent decree.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here